ARTAX BIOPHARMA

Artax Biopharma is developing first-in-class, oral small molecules that inhibit Nck binding to the TCR. Through this novel mechanism, Artax's Nck inhibitors selectively modulate Nck's amplification of the TCR, resulting in a lower T Cell activation and lower T Cell response. Artax believes this process of immunomodulation - during which our medicines assist the immune system to maintain healthy control and eliminate a direct cause of T Cell mediated diseases while not impacting patients' ability to properly fight foreign pathogens - holds great potential... Artax Biopharma is transforming the treatment of T Cell mediated disease... At Artax Biopharma, we believe nothing is more important than patients living their best lives. We are helping to make this vision possible by developing a new way to treat T Cell mediated diseases, such as autoimmune diseases, T Cell malignancies and induced T Cell pathologies.

Primary location: Cambridge United States